{"Q": 1, "answer": "no", "rationale": "'better match' modifies 'match', not a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_20260", "batch_size": 200, "batch_pos": 190, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain a high-potency verb, potent metaphor, superlative + harm noun, intensifier + harm noun, or critical alert phrase.", "method": "llm_batch", "batch_id": "batch_2_16444", "batch_size": 200, "batch_pos": 154, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment describes development/testing, not a realised impact.", "method": "llm_batch", "batch_id": "batch_3_5184", "batch_size": 200, "batch_pos": 74, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
